Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by pet scan after reduced-intensity allogeneic stem cell transplantation in patients with hodgkin lymphoma

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 12, 2014, Pages 1982-1988

  Farina, Lucia ^a   Rezzonico, Francesca ^a   Spina, Francesco ^a   Dodero, Anna ^a   Mazzocchi, Arabella ^a   Crippa, Flavio ^a   Alessi, Alessandra ^a   Dalto, Serena ^a   Viviani, Simonetta ^a   Corradini, Paolo ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Allogeneic stem cell transplantation; Hodgkin lymphoma; Thymus and activation regulated chemokine (TARC)

Indexed keywords

THYMUS AND ACTIVATION REGULATED CHEMOKINE; CCL17 PROTEIN, HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; REED STERNBERG CELL; ADOLESCENT; ALLOGRAFT; BLOOD; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PHYSIOLOGIC MONITORING; RADIOGRAPHY; RECURRENT DISEASE; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADOLESCENT; ADULT; ALLOGRAFTS; CHEMOKINE CCL17; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 84912532991     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.08.016     Document Type: Article

References (33)

1. Shamash J., Lee S.M., Radford J.A., et al. Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. Ann Oncol 2000, 11:715-719.
2. Kewalramani T., Nimer S.D., Zelenetz A.D., et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003, 32:673-679.
3. Peggs K.S., Hunter A., Chopra R., et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005, 365:1934-1941.
4. Anderlini P., Saliba R., Acholonu S., et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008, 93:257-264.
5. Corradini P., Dodero A., Farina L., et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007, 21:2316-2323.
6. Sureda A., Canals C., Arranz R., et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012, 97:310-317.
7. Sarina B., Castagna L., Farina L., et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010, 115:3671-3677.
8. Hart D.P., Avivi I., Thomson K.J., et al. Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Br J Haematol 2005, 128:824-829.
9. Lambert J.R., Bomanji J.B., Peggs K.S., et al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood 2010, 115:2763-2768.
10. Kletter K., Kalhs P. (18)F-deoxyglucose PET: useful in the management of patients with stem cell transplantation for lymphoma?. Expert Rev Hematol 2010, 3:405-410.
11. Wudhikarn K., Brunstein C.G., Bachanova V., et al. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome. Biol Blood Marrow Transplant 2011, 17:1497-1504.
12. Anderlini P., Acholonu S.A., Okoroji G.J., et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant 2004, 34:511-514.
13. Peggs K.S., Sureda A., Qian W., et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007, 139:70-80.
14. Tomblyn M., Lazarus H.M. Donor lymphocyte infusions: the long and winding road: how should it be traveled?. Bone Marrow Transplant 2008, 42:569-579.
15. van den Berg A., Visser L., Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999, 154:1685-1691.
16. Peh S.C., Kim L.H., Poppema S. TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. Am J Surg Pathol 2001, 25:925-929.
17. Weihrauch M.R., Manzke O., Beyer M., et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 2005, 65:5516-5519.
18. Niens M., Visser L., Nolte I.M., et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 2008, 140:527-536.
19. Sauer M., Plütschow A., Jachimowicz R.D., et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol 2013, 88:113-115.
20. Plattel W.J., van den Berg A., Visser L., et al. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica 2012, 97:410-415.
21. Saeki H., Tamaki K. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. JDermatol Sci 2006, 43:75-84.
22. Jones K., Vari F., Keane C., et al. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res 2013, 19:731-742.
23. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. JClin Oncol 2007, 25:571-578.
24. Gopal A.K., Ramchandren R., O'Connor O.A., et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012, 120:560-568.
25. Theurich S., Malcher J., Wennhold K., et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. JClin Oncol 2013, 31:e59-e63.
26. Zijlstra J.M., Lindauer-van der Werf G., Hoekstra O.S., et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006, 91:522-529.
27. Meignan M., Barrington S., Itti E., et al. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma 2014, 55:31-37.
28. Horning S.J., Juweid M.E., Schöder H., et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2010, 115:775-777.
29. Cheson B. The case against heavy PETing. JClin Oncol 2009, 27:1742-1743.
30. Campbell J.J., Haraldsen G., Pan J., et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999, 400:776-780.
31. Terada N., Nomura T., Kim W.J., et al. Expression of C-C chemokine TARC in human nasal mucosa and its regulation by cytokines. Clin Exp Allergy 2001, 31:1923-1931.
32. Wei J., Zhang Y., Xu H., et al. Atopic dermatitis-like presentation of graft-versus-host disease: a novel form of chronic cutaneous graft-versus-host disease. JAm Acad Dermatol 2013, 69:34-39.
33. Creamer D., Martyn-Simmons C.L., Osborne G., et al. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy. Arch Dermatol 2007, 143:1157-1162.